argenex (ARGX) Stock Price, News & Analysis

Company Overview

argenx is a global immunology company focused on the discovery and development of antibody-based therapies for severe autoimmune and inflammatory diseases. Leveraging its proprietary SIMPLE Antibody platform, the company engineers next-generation antibodies designed to engage immune system targets with high specificity. Headquartered in the Netherlands with research and commercial operations in the United States, argenx seeks to translate its deep scientific expertise into novel treatments that address critical, unmet medical needs.

The company’s lead product candidate, efgartigimod (Vyvgart), is a first-in-class neonatal Fc receptor (FcRn) blocker that selectively reduces pathogenic IgG autoantibodies. Efgartigimod is approved in multiple markets for the treatment of generalized myasthenia gravis and is under regulatory review or in late-stage studies for immune thrombocytopenia and other autoimmune disorders. Argenx’s broader pipeline includes bispecific and multispecific antibodies targeting oncology and neuromuscular indications, as well as programs in preclinical development aimed at expanding its immunomodulatory portfolio.

Founded in 2008 by Dr. Tim Van Hauwermeiren and Dr. Roel Opdenbosch, argenx has grown through strategic collaborations with biopharmaceutical partners and academic institutions. The company maintains research sites in Europe and North America, supported by manufacturing capabilities and commercial infrastructure poised to bring therapies to patients worldwide. Argenx’s approach combines cutting-edge antibody engineering with a patient-centric development model to accelerate clinical progress.

Under the guidance of a seasoned leadership team with deep backgrounds in immunology, drug development, and global commercialization, argenx continues to advance its mission of delivering life-changing therapies. The company’s board and executive officers bring decades of industry experience, positioning argenx to navigate regulatory pathways and scale its operations as it transitions from a clinical-stage organization to a fully integrated biopharmaceutical company.

Key Stats

• Today's Range: $557.05 to $571.99
• 50-Day Range: $532.27 to $656.65
• 52-Week Range: $457.42 to $678.21
• Volume: 356,326 shs
• Average Volume: 333,159 shs
• Market Capitalization: $34.35 billion
• P/E Ratio: 34.63
• Dividend Yield: N/A
• Price Target: $728.06
• Consensus Rating: Buy

argenex Stock Analysis - MarketRank™

argenex scored higher than 88% of companies evaluated by MarketBeat, and ranked 124th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

argenex has received a consensus rating of Buy. The company's average rating score is 3.10, and is based on 19 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

argenex has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 246.65%

Earnings Growth

Earnings for argenex are expected to grow by 246.65% in the coming year, from $3.13 to $10.85 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of argenex is 34.63, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.26.

Price to Earnings Ratio vs. Sector

The P/E ratio of argenex is 34.63, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.58.

Price to Earnings Growth Ratio

argenex has a PEG Ratio of 1.03. PEG Ratios around 1 indicate that a company is correctly valued.

Price to Book Value per Share Ratio

argenex has a P/B Ratio of 6.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.31% of the float of argenex has been sold short.

Short Interest Ratio / Days to Cover

argenex has a short interest ratio ("days to cover") of 4.7.

Change versus previous month

Short interest in argenex has recently decreased by 2.48%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

argenex does not currently pay a dividend.

Dividend Growth

argenex does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.31% of the float of argenex has been sold short.

Short Interest Ratio / Days to Cover

argenex has a short interest ratio ("days to cover") of 4.7.

Change versus previous month

Short interest in argenex has recently decreased by 2.48%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 1.02

News Sentiment

argenex has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 14 news articles for argenex this week, compared to 11 articles on an average week.

Search Interest

16 people have searched for ARGX on MarketBeat in the last 30 days. This is an increase of 78% compared to the previous 30 days.

MarketBeat Follows

9 people have added argenex to their MarketBeat watchlist in the last 30 days. This is an increase of 125% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, argenex insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.43% of the stock of argenex is held by insiders.

Percentage Held by Institutions

60.32% of the stock of argenex is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ARGX Stock Analysis - Frequently Asked Questions

How have ARGX shares performed this year?

argenex's stock was trading at $615.00 on January 1st, 2025. Since then, ARGX shares have decreased by 8.7% and is now trading at $561.28.

How were argenex's earnings last quarter?

argenex SE (NASDAQ:ARGX) announced its earnings results on Thursday, May, 8th. The company reported $2.58 EPS for the quarter, topping analysts' consensus estimates of $2.32 by $0.26. The business earned $1.35 billion during the quarter, compared to analyst estimates of $748.34 million. argenex had a net margin of 40.20% and a trailing twelve-month return on equity of 16.15%.
Read the conference call transcript.

When did argenex IPO?

argenex (ARGX) raised $65 million in an IPO on Thursday, May 18th 2017. The company issued 3,600,000 shares at $18.18 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are argenex's major shareholders?

argenex's top institutional investors include Assenagon Asset Management S.A. (0.18%), Perpetual Ltd (0.16%), Park Avenue Securities LLC and Central Pacific Bank Trust Division.

How do I buy shares of argenex?

Shares of ARGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of argenex own?

Based on aggregate information from My MarketBeat watchlists, some other companies that argenex investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Broadcom (AVGO), Taiwan Semiconductor Manufacturing (TSM), CrowdStrike (CRWD) and Adobe (ADBE).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/14/2025
• Next Earnings (Estimated): 7/24/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ARGX
• CIK: 1697862
• Web: www.argenx.com
• Phone: (176) 303-0488
• Fax: N/A
• Employees: 1,599
• Year Founded: N/A

Price Target and Rating

• Average Price Target for argenex: $728.06
• High Price Target: $1,065.00
• Low Price Target: $605.00
• Potential Upside/Downside: +29.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.10
• Research Coverage: 21 Analysts

Profitability

• EPS (Trailing Twelve Months): $16.21
• Trailing P/E Ratio: 34.63
• Forward P/E Ratio: 179.32
• P/E Growth: 1.03
• Net Income: $833.04 million
• Net Margins: 40.20%
• Pretax Margin: 13.67%
• Return on Equity: 16.15%
• Return on Assets: 14.33%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.29
• Quick Ratio: 6.68

Sales & Book Value

• Annual Sales: $2.25 billion
• Price / Sales: 15.25
• Cash Flow: $2.98 per share
• Price / Cash Flow: 188.60
• Book Value: $90.49 per share
• Price / Book: 6.20

Miscellaneous

• Outstanding Shares: 61,200,000
• Free Float: 59,713,000
• Market Cap: $34.35 billion
• Optionable: Optionable
• Beta: 0.37